reports
- ABGSC IT Research
- Øystein Elton Lodgaard
Raffles Medical Group Ltd: 1 director
A director at Raffles Medical Group Ltd bought 1,000,000 shares at 1.020SGD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Metallus Inc: 2 directors
Two Directors at Metallus Inc sold 33,412 shares at between 24.000USD and 24.092USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
MultiPlan Corp: 1 director
A director at MultiPlan Corp bought 160,000 shares at 0.600USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
- Martin Marandon-Carlhian
- Stephane Houri
Arm Holdings plc : Arm remains the key vehicle to play the growing com...
>Outperform rating reiterated, target price increased to $ 130 (vs $ 110) - We did a recap with the company a few days after the release of its Q4 2023-24 results and came away with confirmation that Arm is set to continue to grow at an average of 20% per year over the next three years. Growth, as we wrote in our report initiating coverage of the stock, stems from an accelerated architecture complexification process, driven initially by the acceleration in significant...
BGHL (GBP): NAV(s)
BGHL (GBP): NAV(s) BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company. Close of business 20 May 2024. Estimated NAV Euro Shares Sterling Shares Estimated NAV € 27.8678 £ 24.9732 Estimated MTD return 0.65 % 0.72 % Estimated YTD return 1.16 % 1.64 % Estimated ITD return 178.68 % 149.73 % NAV and returns are calculated net of management and performance fees Ma...
BGHL (EUR): NAV(s)
BGHL (EUR): NAV(s) BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company. Close of business 20 May 2024. Estimated NAV Euro SharesSterling SharesEstimated NAV€ 27.8678£ 24.9732Estimated MTD return 0.65 % 0.72 %Estimated YTD return 1.16 % 1.64 %Estimated ITD return 178.68 % 149.73 % NAV and returns are calculated net of management and performance fees Market information Euro SharesAmsterdam (AEX)London (LSE)...
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-clas...
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within...
Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une c...
Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA Paris, New York, New York et San Francisco, Californie, 21 mai 2024. Sanofi, Formation Bio et OpenAI collaborent afin de construire des logiciels alimentés par l’IA afin d’accélérer le développement de médicaments et de proposer de nouveaux médicaments aux patients de manière plus efficace. Les trois équipes réuniront des données, des logiciels et des modèles adaptés pour développer d...
KKR Invests in Healthcare Revenue Solutions Provider Infinx
MUMBAI, India--(BUSINESS WIRE)-- KKR, a leading global investment firm, and Infinx Services Private Limited (“Infinx” or the 'Company'), an AI-driven healthcare revenue cycle solutions provider, today announced the acquisition of a significant minority stake in Infinx by a KKR-managed fund. Through this investment, KKR will leverage its extensive experience in the global healthcare and technology sectors to accelerate Infinx’s growth, expand the Company’s network, and support bolt-on acquisitions. Norwest Venture Partners, an existing shareholder, also participated in the transaction. This pr...
Nextensa : RESULTS ON Q1 2024
Nextensa : RESULTS ON Q1 2024 REGULATED INFORMATION Brussels, 21 May 2024, 07h30 NEXTENSA: RESULTS ON Q1 2024 HIGHLIGHTS INVESTMENT PROPERTIES • Despite some property sales in 2023 and 2024, rental income in Q1 is higher than in the same quarter last year.• Realisation of like-for-like rental growth of +4.5% in the first quarter of 2024 compared to 2023.• New lease agreement for the Moonar park with Regus (about 1,500 sqm), bringing the park’s lettings to about 80%.• In early February 2024, the retail property of approximately 4,200 m² on rue du Brill in Foetz, Luxem...
NEXTENSA: RÉSULTATS POUR LE Q1 2024
NEXTENSA: RÉSULTATS POUR LE Q1 2024 INFORMATION REGLEMENTEE Bruxelles, 21 mai 2024, 07h30 NEXTENSA: RÉSULTATS POUR LE Q1 2024 FAITS MARQUANTS IMMEUBLES DE PLACEMENT • Malgré la vente de certains actifs en 2023 et 2024, les revenus locatifs du premier trimestre sont supérieurs à ceux du même trimestre de l’année précédente.• Réalisation d’une croissance des loyers à périmètre constant de +4,5% au premier trimestre 2024 par rapport à 2023.• Nouveau contrat de location pour le campus de bureaux Moonar signé par Regus (+/- 1 500 m²), ce qui porte le taux de location du campus à...
- ABGSC IT Research
- Oscar Rönnkvist
- Simon Jönsson
- Olfa Taamallah
- Yan Derocles
Airbus Group : Visite du site de Hambourg – En vol pour la cadence 75
>Une supply chain encore sous tension - Nous avons organisé une visite du site d’Hambourg où nous avons notamment pu échanger avec Thomas Toepfer (CFO) et Christoph Zammert (Head of A320 program). A nos yeux, les points saillants étaient les suivants. Tout d’abord, le discours sur la chaine de fournisseurs reste prudent avec, à court terme, des difficultés centrées sur les fournisseurs Tier 2/3, tout particulièrement dans les domaines de la cabine, l’APU et certains «...
- Gerardo Ibanez
- Steven Boumans
Vastned : Major changes at Vastned: Asset Sales, Synergies and Sven
>Reverse merger of Vastned Retail and Vastned Belgium and new CEO - Vastned’s management is executing its strategic plans: 1) A major step in its asset sales program had been announced earlier; 2) last week the company announced the intention to merge, which should create synergies; and 3) Vastned announced a new CEO from 2025, Sven Bosman. The announced intention to merge its Belgian and Dutch entities in a reverse cross-border merger is expected to be positive for s...
- Martin Marandon-Carlhian
- Stephane Houri
Arm Holdings plc : Arm reste le véhicule clé pour jouer la complexific...
>Opinion Surperformance réitérée, OC relevé à 130 $ (vs 110 $) - Nous avons fait le point avec la société, quelques jours après la publication du T4 23/24, et ressortons confortés sur le fait que Arm devrait continuer de croître en moyenne de 20% par an sur les 3 prochains exercices. Cette croissance découle bien, comme nous l’avions indiqué lors de notre initiation, d’un process accéléré de complexification des architectures, tirée dans un 1er temps par l’accélérati...
Assurant Inc: 2 directors
Two Directors at Assurant Inc sold 9,400 shares at between 176.122USD and 176.363USD. The significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
BMS Birlesik Metal Sanayi ve Ticaret Anonim Sirketi: 2 directors
Two Directors at BMS Birlesik Metal Sanayi ve Ticaret Anonim Sirketi sold 600,000 shares at between 34.070TRY and 34.110TRY. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by ...
Fitness Prime: 1 director
A director at Fitness Prime bought 300,000 shares at 0.000EGP and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Hornbach Holding AG & Co KGaA: 1 director
A director at Hornbach Holding AG & Co KGaA bought 300 shares at 78.399EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.